The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. These innovative therapies are reshaping the approach to both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (R/R MM), offering patients a new beacon of hope with their effective and groundbreaking solutions. This progress in therapy is also significantly impacting the multiple myeloma prognosis, providing more effective multi...
